Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
The FDA Approved Several New Rheumatology Drugs in 2017
Valeant Prices Psoriasis Treatment at $3,500 Per Month
Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
Brodalumab Approved for Plaque Psoriasis
FDA Approves Valeant’s Drug to Treat Plaque Psoriasis